Vericel Secures FDA Approval for Advanced Cell Therapy Manufacturing Facility to Expand MACI Production
Key Insights
Vericel Corporation received FDA approval for commercial MACI manufacturing at its new Burlington, Massachusetts facility, marking a significant regulatory milestone for the cell therapy company.
The approval enables commercial production to begin in the second quarter of 2026, substantially increasing manufacturing capacity to meet growing demand for the cartilage repair therapy.
The expanded manufacturing capability positions Vericel to potentially commercialize MACI outside the United States for the first time.
Vericel Corporation announced that the U.S. Food and Drug Administration has granted approval for commercial manufacturing of MACI (autologous cultured chondrocytes (search) on porcine collagen membrane) at its new cell therapy manufacturing facility in Burlington, Massachusetts. The regulatory milestone enables the company to begin commercial production at the facility in the second quarter of 2026, substantially expanding manufacturing capacity for its cartilage repair therapy.
Manufacturing Expansion and Strategic Impact
The FDA approval allows Vericel to leverage its state-of-the-art facility to meet increasing demand for MACI, an autologous cellularized scaffold product indicated for repairing symptomatic cartilage defects (search) of the knee. The expanded manufacturing capability also positions the company to potentially commercialize MACI outside the United States for the first time, representing a significant growth opportunity.
"This FDA approval reflects a major achievement for Vericel and underscores the Company's operational and scientific expertise in complex cell therapy manufacturing," said Nick Colangelo, President and Chief Executive Officer of Vericel. "Bringing our Burlington facility online for commercial MACI production strengthens our supply chain and supports our mission to deliver innovative, high-quality therapies to patients."
MACI Therapy Profile
MACI is an autologous cultured chondrocyte therapy designed for the repair of single or multiple full-thickness cartilage defects (search) of the knee with or without bone involvement in adults. The therapy utilizes the patient's own cells cultured on a porcine collagen membrane, representing an advanced approach to cartilage restoration in the sports medicine market.
Company Portfolio and Market Position
Vericel operates as a leader in advanced therapies for sports medicine and severe burn care markets, combining innovations in biology with medical technologies. Beyond MACI, the company's portfolio includes Epicel (search) (cultured epidermal autografts) for treating patients with severe burns (search) covering 30% or more of total body surface area, and holds exclusive North American rights to NexoBrid (anacaulase-bcdb) for eschar removal in thermal burn patients.
The Burlington facility approval represents a critical operational milestone that strengthens Vericel's manufacturing infrastructure and supports the company's long-term growth strategy in the advanced therapy market.